Latest Commentary

Track-and-trace is here ... and now

The industry has been talking about, and slowly working toward, track-and-trace for many years. Now Pharma faces real deadlines that require action.

Look for more Fierce effort in 2013

The holiday's are upon us and we realize many of our readers will be taking a break. We intend to join you. The next issue of FiercePharmaManufacturing will be Jan. 3, after the holidays.

Pilot shows national track and trace 'not insurmountable'

It looks like a national track and trace system is going to be implemented in the U.S. sooner rather than later. Differences between what industry believes it is capable of handling and what regulators believe it must kept it out of the FDA reauthorization bill, but no one should think that put it into the deep freeze.

An FDA warning letter often means a tipping point has been reached

Every week there is some news, recall or event that reminds us that the give and take with the FDA over manufacturing often means poor GMPs give companies major headaches and take a lot of time and money to resolve. The examples you will find in our 2012 FDA Red Flags Report are not all tipping point examples, but many are.

Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays'

Getting clinical trials right, and right the first time, is crucial for biopharma companies, especially as the cost of getting a drug to market is skyrocketing. Matthew Herper estimates in "The...

Here are some tips on cargo theft that might save you $75M

U.S. manufacturers have made a giant leap forward in protecting against cargo theft.

Check out the new and improved FiercePharmaManufacturing website

We've completed a major overhaul of FiercePharmaManufacturing's website. Drop us a line with any suggestions or comments you may have.

Providing insight into pharmaceutical manufacturing requires conversation

Take a look at a recent graph of health spending in the U.S., and you may see a visual metaphor for what faces drug manufacturing.

Pfizer revels in massive Prevnar vax job

Pfizer ($PFE) announced in December it had extended its advance market commitment (AMC) to the Global Alliance for Vaccine and Immunisation (GAVI) for the pneumococcal vaccine Prevnar 13. The drug

Novartis, Lundbeck score wins for manufacturing in the West

Kudos to the Novartis ($NVS) ops team in Nyon, Switzerland! They've persuaded execs to keep open an OTC drug-making plant that the company had doomed to closure last fall. The company also has agreed